Potential COVID-19 therapeutics from a rare disease: weaponizing lipid dysregulation to combat viral infectivity
Preclinical studies in the published literature have examined BPC-157 in the context of connective-tissue cell migration assays, gastrointestinal epithelial models, and angiogenic signalling pathways
Its main mechanism appears to be its interaction with the nitric oxide (NO) system and its ability to upregulate growth factors like Vascular Endothelial Growth Factor (VEGF)
Citation: Vukojevi, J., Kolenc, D., Brcic, I., & Seiwerth, S
SLU-PP-332 is used in research to develop new treatments for metabolic diseases and to study the effects of exercise mimetics on animals metabolism
This effect is dose-dependent and typically transient, resolving as patients acclimate to therapy